Tags : Split Dosing Regimen

Genmab’s Darzalex (daratumumab) Split Dosing Regimen Receives the US FDA

Vartika Singh February 12, 2019

Shots: The approval is based on P-Ib EQUULEUS (MMY1001) results assessing Darzalex in 240 patients with multiple myeloma and safety profile of Darzalex when administered single dose or split dose […]readmore

Tags : Split Dosing Regimen

Genmab’s Darzalex (daratumumab) Split Dosing Regimen Receives the US FDA

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Split Dosing Regimen

Genmab’s Darzalex (daratumumab) Split Dosing Regimen Receives the US FDA

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company